In lung cancer, an alginate hydrogel embedding endoplasmic reticulum (ER)-modified liposomes co-delivering STAT3 siRNA and lidocaine achieved single-application tumor control, tumor-associated macrophage (TAM) repolarization, natural killer cell (NK) activation, pleural effusion reduction, and analgesia in postoperative non-small cell lung cancer (NSCLC) models, exemplifying local immunoanalgesic management [37], while a focused review delineates formulation advances and translational hurdles specific to siRNA-loaded liposomes in this disease [17]. The gene discussed is STAT3; the disease is neoplasm.